PRME heads into its June 5 earnings call with short positioning at its most crowded level in months and the borrow market tightening sharply — a setup that puts maximum pressure on whatever the company delivers next week.
Short interest has climbed steadily, reaching 29.4% of the free float. That is up from roughly 27.7% a month ago and marks the highest level in the 30-day window. The move has been gradual but relentless — 32 million shares short is a heavy bet against a stock trading under $3. The ORTEX short score reflects that pressure: 82.8, barely changed over the past ten sessions but sitting near its highest recent readings. Days-to-cover from the latest FINRA filing runs at 11.7 — short sellers would need almost two and a half weeks of average volume just to exit.
The borrow market has tightened sharply this week. Availability has dropped to 21.2% — meaning only about one share in five is still available to borrow relative to what's already on loan. That compares with 59.5% available just two weeks ago. The 52-week minimum availability was near zero, so there is room to tighten further, but the rapid move from loose to tight in less than a fortnight is notable heading into a binary catalyst. Cost to borrow remains modest at 0.76% — not a squeeze-level rate — but the tightening availability suggests demand for borrows is accelerating ahead of the print. Options positioning has also edged more defensive over the week. The put/call ratio has risen to 0.48, above its 20-day average of 0.43. That is not an extreme reading by historic standards — the 52-week high is 0.51 — but the direction of travel over the past two weeks has been consistently higher.
The Street's view is firmly bullish in aggregate, but the most recent named activity worth citing dates from March. Oppenheimer initiated at Outperform with an $11 target then, a level the stock has not been near in a long time. The mean price target across eight buy ratings is $6.92 against a current price of $2.97 — implying significant upside if clinical catalysts materialise. The bear case centres on regulatory risk to lead programs PM577 and PM647, where complexity and timeline uncertainty could extend the cash-consumption runway without delivering investor returns. The bull case rests on prime editing's differentiation — the technology is designed to avoid bystander edits that plague earlier CRISPR approaches — and on potential arbitration resolutions providing near-term catalysts. Stock scores offer little comfort on quality: the quality percentile is in the low-to-mid teens and has been sliding all month, while value ranks in the high 20s. Momentum is the one area holding up, around the 58th percentile, supported partly by the 10% weekly gain.
The stock's own history of earnings reactions deserves a look. The most recent print, on May 7, was the worst: the stock fell 5.9% on the day and lost 8.2% over the following five sessions. The March 9 event saw only a modest 1% gain on the day before a 8.5% slide over the week. The sole green five-day outcome in recent history came from the May 8 event — a 4% day-one gain that still reversed to a 5.9% loss by day five. None of the four recent earnings prints have produced a sustained positive move; the five-day return was negative in every case.
Peer context reinforces the divergence. Gene-editing neighbour EDIT gained 21.7% on the week and BEAM added 11.1%, while CRSP rose 6.2%. PRME's 10% gain partially closes the gap, but the stock has shed 20% over the past month — a trajectory that puts it well behind the cohort even after this week's recovery.
With the June 5 call just days away, the key variable is clinical data flow on Wilson Disease and AATD programs rather than financial results. Availability continuing to tighten through the week would indicate shorts are not covering ahead of the event — a signal worth watching alongside any pre-print data release or conference presentation.
See the live data behind this article on ORTEX.
Open PRME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
